To this end, we combined IMC data obtained from biopsy samples from melanoma patients precheckpoint therapy, the data regarding the response of these patients to anti-PD1/CTLA4 checkpoint therapy to develop a mechanistic spatially resolved interacting cell system (ICSs) model; we combined statistical interference theory to justify details of the interactions between immune and tumor cells that underlie patient responses to immune checkpoint inhibition (ICI) drugs. Here, CTLA4 is linked to melanoma.